Specifically, compared with either therapy administered alone to the HCC tumor-bearing syngeneic model mice, a combination treatment consisting of FXR agonist plus an anti‐PD‐1 Ab obviously inhibited tumor development and showed potent antitumor ability. The gene discussed is NR1H4; the disease is neoplasm.